ARS Pharma Reports Strong Neffy Revenue Growth Amid Increased Commercialization Spend and Ongoing Legal Battles
SPRY sits 20% above its 52-week low of $6.66.
Summary
ARS Pharmaceuticals reported robust Q1 2026 revenue growth for Neffy, driven by strong commercialization efforts, but also saw a wider net loss and is engaged in multiple legal disputes.
Key Events · Earnings and Guidance · SPRY
-
Significant Revenue Growth
Total revenue increased 184% year-over-year to $22.7 million for Q1 2026, with U.S. net product revenue for Neffy rising 125% to $17.5 million. This follows the news release on the same day, providing full financial context.
-
Increased Net Loss Due to Commercialization
Net loss widened to $60.6 million in Q1 2026 from $33.9 million in Q1 2025, primarily driven by a substantial increase in selling, general, and administrative expenses to $72.2 million (up 76% YoY) for Neffy's commercial launch.
-
Strong Commercial Traction for Neffy
Over 28,000 healthcare providers have prescribed Neffy, with approximately 120,000 patients using it in the U.S. as of the end of Q1 2026. Commercial insurance coverage is approximately 90% overall.
-
Global Regulatory and Commercial Expansion
Neffy received an FDA label update removing age criteria for the 1 mg dose, Health Canada approval, and launched in China, Japan, and Australia through collaboration partners.
Analysis · SPRY · Life Sciences
This quarterly report highlights significant commercial progress for Neffy, with substantial revenue growth and increasing patient adoption. However, the company's net loss has widened due to aggressive commercialization investments. The ongoing patent infringement lawsuits against generic competitors and trade secret litigation represent material risks that could impact future revenue streams and operational focus. Investors will be weighing the strong market penetration against the increased cash burn and legal uncertainties.
At the time of this filing, SPRY was trading at $7.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $788.4M. The 52-week trading range was $6.66 to $18.90. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.